Translate page

-- Virtual Education Program: 2014 Edition

giorasharf  

Non-adherence of CML patients
Results of the global adherence survey of the CML Advocates Network
Giora Sharf, CML Advocates Network

  • Results of the global adherence survey of 2546 CML patients from 79 countries
  • Intentional and non-intentional non-adherence levels
  • Differences between countries, type of TKI, administration schedule, age groups, perception of quality of life and side effects
  • Tools to drive adherence and importance of routines

-- Virtual Education Program: 2012 Edition

(We are very grateful for the support of Brandcast media to produce these web streams)

jane-apperley  

Pregnancy in Chronic Myeloid Leukemia
Jane Apperley, Imperial College London, UK

  • Effect of CML and its treatments on fertility of women and men
  • Effect of pregnancy on CML and its treatment
  • Effect of CML and CML treatments on pregnancy
  • Timing of pregnancy in relation to diagnosis of CML
  • Case studies of pregnancies
delphine-rea    

Can we safely stop TKI therapies? Experience from the STOP trials

Delphine Rea, Hôpital Saint-Louis, Paris, France

  • Unmet medical needs in currently available CML treatments
  • Treatment options for CML with T315I mutation
  • Treatment options after TKI intolerance
  • Trial results with bosutinib, ponatinib, omacetaxine
  • Results from studies investigating imatinib + interferon
jorge-cortes-en  

New Drugs in the Treatment of CML

Jorge Cortes, MD Anderson Cancer Center, Houston, USA

  • Unmet medical needs in currently available CML treatments
  • Treatment options for CML with T315I mutation
  • Treatment options after TKI intolerance
  • Trial results with bosutinib, ponatinib, omacetaxine
  • Results from studies investigating imatinib + interferon

 

-- Virtual Education Program: 2011 Edition

(We are very grateful for the support of Brandcast media to produce these web streams)

vep_branford_molecmonitoring  

The Importance of Molecular Monitoring in CML

Susan Branford, Australia 

  • Measurement of BCR-ABL transcript levels to assess residual disease
  • Recommended monitoring for CML
  • The significance of achieving a major molecular response
vep_branford_mutationanalysis    

The importance of BCR-ABL kinase domain mutation analysis in CML

 Susan Branford, Australia

  • Mutations as a mechanism of imatinib resistance
  • Why mutations arise
  • When to test for mutations
  • Therapeutic options in the presence of mutations
vep_radich_transplant  

Transplantation for CML in 2011: Who, why, when?

Jerry Radich, Seattle, USA

  • Definition of optimal response to imatinib
  • Managing suboptimal response, case study
  • Adherence and molecular response
  • Role of mutations, criteria for mutation screening on 1st line therapy
  • Dose related toxicities with TKI’s; concomitant medications
   

 

 

Click here to see the Virtual Education Program modules of 2010, featuring John Goldman, Michele Baccarani, Tim Hughes and Pat Garcia-Gonzalez.